Stock Ratings / Health Care / AVIR / financials

ARCT (31) CTNM (40) GALT (42) CYPH (40) ⌘ Pro Terminal →

Atea Pharmaceuticals Inc. (AVIR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$4.31 +0.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.31

Atea Pharmaceuticals Inc. (AVIR) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $345.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.31 (-0.02%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AVIR)Realized 20D OHLCV Swing Band: ±11.6%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY AVIR SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (25% of score)

FRED Regime × Technicals: 40% of 52W Range • RSI-14 at 32.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$5.15-16.1% Next Q

Q2 (-2Q)

Grade D$4.32-6.5% Next Q

Q3 (-1Q)

Grade D$4.04+6.7% Next Q

Current

Grade D-$4.31-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AVIR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AVIR currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.04) and Max Pain ($4.53) forces dealer call-delta covering toward $6.77.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AVIR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AVIR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How AVIR Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-4.5%	-$158.0M	-$132.0M	-45%
FY 2024	$4.00B	52%	-4.8%	-$168.0M	-$135.5M	-40.7%
FY 2023	$4.00B	52%	-4.1%	-$136.0M	-$85.4M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AVIR)

✓Walkthrough of AVIR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AVIR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.78%▲ ASCENDING CHANNEL

2026-10-30O $4.30H $4.32L $4.07C $4.31VOL 349.9K

RES: $6.54SUP: $3.94SMA50: $5.04SMA200: $4.93

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AVIR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AVIR Butterfly Map → + Track AVIR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AVIR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AVIR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AVIR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AVIR)

Health Care Rank #640 of 1016 ⚔️ ARCT vs AVIR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AVIR vs. ARCT, CTNM, GALT, CYPH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Atea Pharmaceuticals Inc. (AVIR) ranks #640 by composite RQD confidence (40/100, grade D-) and #502 by equity capitalization ($345.7M). Within this direct 5-issuer industry benchmark cohort, CYPH leads on earnings valuation at 71.3x trailing P/E, while CYPH leads on capital efficiency and profitability with -23.3% ROIC and — gross margin. GALT currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with AVIR at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AVIR ACTIVE Atea Pharmaceuticals Inc.	D-	40/100	—	—	-35.0%	+0.94%	$345.7M	Benchmark Subject
ARCT Arcturus Therapeutics Holdings Inc.	E	31/100	—	—	-35.0%	+0.66%	$345.3M	/arct-vs-avir →
CTNM Contineum Therapeutics Inc. (Class A)	D-	40/100	—	—	-29.0%	+1.97%	$351.0M	/ctnm-vs-avir →
GALT Galectin Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.56%	$355.8M	/galt-vs-avir →
CYPH Cypherpunk Technologies Inc.	D-	40/100	71.3x	—	-23.3%	+2.16%	$356.7M	/cyph-vs-avir →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001593899

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Atea Pharmaceuticals Inc. (AVIR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$158.0M, operating cash flow of -$132.0M, and free cash flow of -$132.0M (+2.6% YoY). On the balance sheet, AVIR closed FY2025 with $315.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$158.0M	-$132.0M	-$132.0M	$315.2M	—
FY2024 (FY)	2024-12-31	$0	-$168.0M	-$135.5M	-$135.5M	$464.7M	—
FY2023 (FY)	2023-12-31	$0	-$136.0M	-$85.4M	-$85.4M	—	—

3. AVIR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AVIR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Atea Pharmaceuticals Inc. (NASDAQ: AVIR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $4.31 (+0.94% 1D, market cap $345.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AVIR ranks #640 in composite RQD confidence.

How does AVIR compare to ARCT and CTNM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AVIR carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARCT (Arcturus Therapeutics Holdings Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $345.3M) and CTNM (Contineum Therapeutics Inc. (Class A)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -29.0%, cap $351.0M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AVIR?

Per AVIR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001593899), Atea Pharmaceuticals Inc. generated $0 in revenue, -$158.0M in net income, and -$132.0M in free cash flow against $315.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AVIR trading relative to its 50-day, 200-day, and 52-week technical levels?

AVIR last traded at $4.31 (+0.94% on volume of 280,876 shares), positioning the stock -14.48% below its 50-day simple moving average ($5.04) and -12.58% below its 200-day simple moving average ($4.93). Across its 52-week range of $2.87 to $6.45, AVIR sits at the 40.2% percentile with a 14-day RSI of 32.4 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($3.81 to $4.81).

AVIR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Atea Pharmaceuticals Inc. (AVIR)?

In FY 2025 (10-K), AVIR converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: AVIR RQD Cockpit AVIR 12M Forecast AVIR Earnings & Move AVIR Dividends & DRIP AVIR Insiders & 13F AVIR Whale Options AVIR Profit Sankey AVIR News & Why